Brief: Elicio Therapeutics Presents Updated Preliminary Data From The Early-Stage Study Of Eli-002 At Aacr Special Conference Pancreatic Cancer
27/09/2023 22:54
Sept 27 (Reuters) - Elicio Therapeutics Inc ELTX.O :
* ELICIO THERAPEUTICS PRESENTS UPDATED PRELIMINARY DATA
INCLUDING
PROMISING RELAPSE-FREE SURVIVAL DATA FROM THE PHASE 1 STUDY OF
ELI-002 AT AACR SPECIAL CONFERENCE: PANCREATIC CANCER
* ELICIO THERAPEUTICS INC - PLANS TO INITIATE A RANDOMIZED
PHASE 2
STUDY EARLY IN 2024 FOR ELI-002 7P
Source text for Eikon: ID:nGNX4nxql0
Further company coverage: ELTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)